Trastuzumab Conjugate BI-CON-02

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** A conjugated form of trastuzumab, a humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; ERBB2), with potential immunomodulating and antineoplastic activities. Upon administration, the trastuzumab conjugate BI-CON-02 targets and binds to HER2 on the tumor cell surface, thereby inducing both cytotoxic T-lymphocyte (CTL) and antibody-dependent cell-mediated cytotoxicity (ADCC) responses against tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.

**Synonyms:** - BI-CON-02